Allarity Therapeutics Management
Management criteria checks 1/4
Allarity Therapeutics' CEO is Thomas Jensen, appointed in Jan 2004, has a tenure of 2.5 years. directly owns 0% of the company’s shares, worth $0.90. The average tenure of the management team and the board of directors is 0.3 years and 2.3 years respectively.
Key information
Thomas Jensen
Chief executive officer
US$24.7k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 21yrs |
| CEO ownership | 0.00002% |
| Management average tenure | less than a year |
| Board average tenure | 2.3yrs |
CEO
Thomas Jensen (46 yo)
21yrs
Tenure
US$24,720
Compensation
Mr. Thomas H. Jensen is Co-Founder of Allarity Therapeutics, Inc. and serves as its Director since July 7, 2022. He is Chief Executive Officer since December 08, 2023 at Allarity Therapeutics, Inc. and ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21yrs | US$24.72k | 0.000020% $ 0.9 | |
| Founder & Chief Scientific Officer | 21yrs | US$266.22k | 0.000020% $ 0.9 | |
| President & Chief Development Officer | less than a year | no data | no data | |
| Co-Founder | no data | US$128.02k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Consultant Chief Medical Officer | less than a year | no data | no data |
0.3yrs
Average Tenure
58.5yo
Average Age
Experienced Management: ALLR's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 2.5yrs | US$24.72k | 0.000020% $ 0.9 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman of the Board | 2.3yrs | US$107.38k | 0.000020% $ 0.9 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.4yrs | US$29.17k | no data | |
| Independent Director | 1.4yrs | US$27.71k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data |
2.3yrs
Average Tenure
57yo
Average Age
Experienced Board: ALLR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 04:33 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Allarity Therapeutics, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathaniel Calloway | Edison Investment Research |
| Aydin Huseynov | Ladenburg Thalmann & Company |